SLS

SELLAS is a late-stage clinical biopharma with zero approved products and zero product revenue; the company states plainly it 'may never generate such revenues or achieve profitability.' The income statement reflects this: a $26.9M net loss in FY2025 (improved from -$30.9M in FY2024 and -$41.3M in FY2022) and -$28.4M of operating cash flow. The lone reported 'revenue' line is FY2023 at $0.00 — there is no commercial business to underwrite a fundamentals-based call. Returns on capital are deeply negative (ROE -37.9%) against a -$275M accumulated deficit, and every dollar of value here is an option on clinical success, not on earnings.

The one genuine strength is the balance sheet. A FY2025 capital raise (shares outstanding +97.7%, equity +648.8%) lifted cash to $71.8M with total liabilities of just $7.47M and no long-term debt (liabilities/equity 0.11x). Against ~$28M annual operating burn, that is roughly two-plus years of runway — enough to reach the catalyst without an immediate financing gun to the head, though the heavy dilution to get there is itself a cost shareholders already bore and may bear again. Management explicitly warns losses will 'increase' as it funds the Phase 3 REGAL trial and SLS009.